8-K: Arrowhead Pharma Reports Q2 FY26 Results, REDEMPLO Momentum

Arrowhead Pharmaceuticals announced its fiscal 2026 second quarter results, highlighting strong commercial execution for REDEMPLO and advancements in its R&D pipeline.

Summary

• Arrowhead Pharmaceuticals reported its fiscal 2026 second quarter financial results for the period ended March 31, 2026.
• The company announced strong execution in meeting and exceeding commercial, R&D, and corporate goals, positioning for near-term growth and long-term shareholder value.
• Key focus areas include strengthening the commercial presence for REDEMPLO, advancing its RNAi therapeutics pipeline, and disciplined financial management.
• REDEMPLO (plozasiran) has shown significant commercial momentum since its U.S. FDA approval on November 18, 2025, with over 400 total prescriptions received and in process.
• Approximately 180 patients have received REDEMPLO shipments, with new weekly prescriptions averaging around 30.
• The company secured positive regulatory actions for REDEMPLO in Australia, Europe (CHMP positive opinion), China (approved and marketed by Sanofi), and Canada (expected availability later in 2026).
• New long-term data for plozasiran showed an 83% median reduction in triglycerides for severe hypertriglyceridemia patients.
• Arrowhead initiated a Phase 1/2a trial for ARO-DIMER-PA, a dual-target RNAi therapeutic for ASCVD.
• Interim data for obesity candidates ARO-INHBE and ARO-ALK7 showed significant weight loss and fat reduction.
• Arrowhead entered an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, receiving a $25 million upfront payment and potential milestone payments up to $975 million.
• The company strengthened its balance sheet through public offerings, raising $930 million in gross proceeds from convertible senior notes and common stock issuance.
• Net loss for the quarter was $132.7 million, or $0.93 per share, compared to a net income of $370.4 million, or $2.75 per share, in the prior year's quarter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed result. While commercial execution and pipeline advancements are positive, the significant year-over-year decline in revenue and the resulting net loss are concerning.

Positives

• REDEMPLO commercial momentum: over 400 prescriptions received/in process, exceeding 40% growth in four weeks.
• Approximately 180 patients have received REDEMPLO shipments.
• New weekly REDEMPLO prescriptions averaging ~30, with 85% of new prescriptions for patients naive to the APOC3 class.
• Positive regulatory actions for REDEMPLO in Australia, Europe (CHMP opinion), China (approved), and Canada (expected).
• Long-term plozasiran data shows 83% median triglyceride reduction in severe hypertriglyceridemia patients.
• Initiation of Phase 1/2a trial for ARO-DIMER-PA, a novel dual-target RNAi therapeutic.
• Promising interim data for obesity candidates ARO-INHBE and ARO-ALK7 showing significant weight and fat loss.
• Exclusive license agreement for ARO-PNPLA3 with Madrigal Pharmaceuticals, including $25M upfront and up to $975M in milestones.
• Strengthened balance sheet with $930 million in gross proceeds from recent public offerings.

Negatives

• Net loss of $132.7 million for the quarter, compared to a net income of $370.4 million in the prior year's quarter.
• Revenue for the quarter was $73.7 million, a significant decrease from $542.7 million in the prior year's quarter.
• Operating expenses increased to $215.0 million from $161.5 million in the prior year's quarter.

Risks

• Potential for adverse reactions to REDEMPLO, including hyperglycemia, headache, nausea, and injection site reactions.
• Regulatory decisions in Europe are still pending for REDEMPLO.
• The company's ability to finance its operations and the success of future clinical trials are subject to various risks.
• Competition from other APOC3 inhibitors and future therapies for hypertriglyceridemia and other diseases.
• Pricing and reimbursement decisions for REDEMPLO and other products could impact market access and revenue.
• The enforcement of intellectual property rights is crucial for the company's success.

Future Outlook

The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value. Key focus areas for sustainable growth include strengthening the commercial presence for REDEMPLO, delivering best-in-class discovery, development, and regulatory capabilities for its RNAi pipeline, and being strategic and disciplined around pipeline, portfolio, and financial management.

Management Comments

• Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals.
• The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value.
• We remain focused on a few key areas as being critical sources of sustainable growth for Arrowhead, and we have made tangible advancements across these areas.
• These include: strengthening our commercial presence to bring REDEMPLO and potentially other cardiometabolic products in the future to the many patients and physicians who need it; continuing to deliver best-in-class in discovery, development, and regulatory capabilities in support of a deep pipeline of RNAi therapeutics capable of silencing and genes expressed throughout the body to treat various diseases; and, being strategic and disciplined around pipeline, portfolio, and financial management.

Industry Context

StockSavvy.ai notes that Arrowhead Pharmaceuticals' results reflect the ongoing advancements in RNA interference (RNAi) therapeutics and the increasing focus on precision medicine for rare and complex diseases. The strong commercial uptake of REDEMPLO and the strategic licensing of ARO-PNPLA3 highlight the company's ability to navigate both commercialization and pipeline development in a competitive biopharmaceutical landscape.

Comparison to Industry Standards

• REDEMPLO's prescription growth rate of over 40% in four weeks is a strong indicator of market acceptance, particularly for a therapy targeting a rare disease like FCS.
• The median triglyceride reduction of 83% for severe hypertriglyceridemia patients with plozasiran data aligns with or exceeds benchmarks for triglyceride-lowering therapies.
• The initiation of a dual-target RNAi therapeutic (ARO-DIMER-PA) is at the forefront of innovation, aiming to address multiple genetic drivers of disease, a trend seen in advanced drug development.
• The weight loss achieved by ARO-INHBE in combination with tirzepatide (-9.4% vs. -4.8%) demonstrates a potential best-in-class profile for combination obesity therapies.
• The $930 million capital raise indicates strong investor confidence in Arrowhead's platform and pipeline, a common strategy for biopharma companies to fund extensive clinical development.

Stakeholder Impact

• Shareholders: Potential for long-term value creation, but short-term financial performance shows a significant loss.
• Patients: Continued access to REDEMPLO for FCS patients, with potential for new treatments for ASCVD and obesity.
• Physicians: Growing adoption of REDEMPLO, with new treatment options emerging from the pipeline.
• Payers: REDEMPLO's unified pricing model aims to simplify contracting and negotiations.

Next Steps

• European Commission decision on REDEMPLO's Marketing Authorization expected in Q2 2026.
• REDEMPLO expected to be available in Canada later in 2026.
• Continue to strengthen commercial presence for REDEMPLO.
• Advance discovery, development, and regulatory capabilities for RNAi therapeutics pipeline.
• Be strategic and disciplined around pipeline, portfolio, and financial management.
• Madrigal Pharmaceuticals to advance ARO-PNPLA3 development under the license agreement.

Key Dates

Recommendation

The company shows strong progress in its pipeline and commercialization of REDEMPLO, evidenced by prescription growth and new regulatory approvals. However, the significant year-over-year decline in revenue and the substantial net loss warrant a cautious 'hold' rating until financial performance stabilizes and revenue trends improve.

Keywords

Arrowhead Pharmaceuticals, 8-K, REDEMPLO, plozasiran, RNAi therapeutics, financial results, fiscal 2026, hypertriglyceridemia